The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
High overall, event-free survival seen at 24 and 36 months for severe combined immunodeficiency due to ADA deficiency
The new expiration date for cutaquig is valid for 42 existing lots that were manufactured and distributed in 2019 and 2020.
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.
ChemoCentryx, Inc has submitted a NDA to the Food and Drug Administration (FDA) for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
TLY012, a PEGylated recombinant human TRAIL (TNF-related apoptosis-inducing ligand) protein, binds upregulated death receptor 5 (DR5) on myofibroblasts (MFBs) and selectively blocks activation of MFBs in fibrotic regions.
The FDA has granted Fast Track designation to telitacicept (RC18; RemeGen) for the treatment of systemic lupus erythematosus.
